Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
Epistemonikos ID: f352218d0e47d19592c37455bdec56e1b2b71d92
First added on: Mar 01, 2025